SCM
VNDA icon

Soleus Capital Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Soleus Capital Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-158,700
Closed -$2.49M – 78
2021
Q4 		$2.49M Sell
158,700
-139,900
-47% -$2.44M 0.25% 52
2021
Q3 		$5.12M Buy
+298,600
New +$5.23M 0.8% 36
2020
Q2 		– Sell
-19,000
Closed -$197K – 71
2020
Q1 		$197K Buy
+19,000
New +$236K 0.23% 45

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EIP
Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Soleus Capital Management's VNDA Position: Q1 2022 in Review

Soleus Capital Management sold out of Vanda Pharmaceuticals (VNDA) in Q1 2022, closing a stake of 158,700 shares — an estimated $2.49M sold.

Soleus Capital Management first reported a position in VNDA in Q1 2020 and held it in 3 quarters. The position peaked at $5.12M in Q3 2021. 188 funds tracked by Wall St. Rank hold VNDA as of Q1 2022.

  • Soleus Capital Management reported no remaining Vanda Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Soleus Capital Management sold 158,700 Vanda Pharmaceuticals shares in Q1 2022, an estimated $2.49M.
  • Soleus Capital Management first reported a position in Vanda Pharmaceuticals in Q1 2020 and held it in 3 quarters.
  • Soleus Capital Management's Vanda Pharmaceuticals position peaked at $5.12M in Q3 2021.
  • 188 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2022.

Based on Soleus Capital Management's 13F filing for Q1 2022, filed 16 May 2022.